新型冠狀病毒

Germany clashes with other EU states on pharma regulation overhaul
德國與歐盟其他國家就製藥業監管改革發生衝突

Berlin warns shortening time before generic drugs are allowed to market will stifle industry investment
柏林方面警告稱,縮短仿製藥獲准上市前的時間將扼殺製藥行業投資。

Germany and several smaller member states have mounted opposing last-ditch lobbying efforts over EU pharmaceutical legislation to be published next week, with Berlin warning that it would damage investment by the drug industry.   

德國和幾個較小的歐盟成員國就歐盟將於下週公佈的藥品立法立場衝突,正在進行各自最後的遊說。柏林方面警告稱,此次改革將損害製藥業的投資。

您已閱讀6%(296字),剩餘94%(4573字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×